GeneDx Holdings (WGS) Gross Margin (2020 - 2026)
GeneDx Holdings' (WGS) quarterly Gross Margin came in at 68.37% in Q2 2026, down 68.0% year-over-year from 213.64% in Q2 2025, and up 2.49% quarter-over-quarter from 66.71% in Q1 2026.
Powered by 
Analysis
GeneDx Holdings (WGS) Gross Margin (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has reported Gross Margin for 7 consecutive years, with 68.37% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin fell 68.0% year-over-year to 68.37% in Q2 2026; TTM through Jun 2026 was 69.37%, a 219.0% increase from a year earlier, with the FY2025 full-year figure at 69.74%, up 610.0% from the prior year.
- Gross Margin was 68.37% for Q2 2026 at GeneDx Holdings, up from 66.71% in the prior quarter.
- Over five years, Gross Margin peaked at 72.4% in Q3 2025 and troughed at 81.83% in Q2 2022.
- A 5-year average of 42.15% and a median of 60.42% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin plunged 7936 bps in 2022 and soared 12034 bps in 2023, its largest moves.
- Over 5 years, Gross Margin stood at 26.61% in 2022, then jumped by 301 bps to 53.56% in 2023, then rose by 29 bps to 69.22% in 2024, then rose by 1 bps to 69.65% in 2025, then declined by 2 bps to 68.37% in 2026.
- The last three Gross Margin figures came in at 68.37% (Q2 2026), 66.71% (Q1 2026), and 69.65% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 53.05 Bn | 51.95 Bn | 486.15 Mn | 64.58% |
| 2 | Quest Diagnostics | 27.19 Bn | 26.87 Bn | 1.03 Bn | 33.75% |
| 3 | Labcorp Holdings | 25.93 Bn | 25.81 Bn | 1.11 Bn | 29.80% |
| 4 | Guardant Health | 23.97 Bn | 22.91 Bn | 219.03 Mn | 65.39% |
| 5 | Tempus AI | 13.64 Bn | 12.82 Bn | 274.25 Mn | 71.70% |
| 6 | Caris Life Sciences | 8.47 Bn | 7.68 Bn | 182.38 Mn | 69.16% |
| 7 | Sotera Health | 5.35 Bn | 4.99 Bn | 177.96 Mn | 55.38% |
| 8 | BillionToOne | 4.96 Bn | 4.41 Bn | 77.11 Mn | 70.45% |
| 9 | Adaptive Biotechnologies | 4.55 Bn | 4.21 Bn | 51.39 Mn | 71.82% |
| 10 | GeneDx Holdings | 3.01 Bn | 2.88 Bn | 78.24 Mn | 68.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 68.37% |
| Mar 31, 2026 | 66.71% |
| Dec 31, 2025 | 69.65% |
| Sep 30, 2025 | 72.40% |
| Jun 30, 2025 | 69.04% |
| Mar 31, 2025 | 67.13% |
| Dec 31, 2024 | 69.22% |
| Sep 30, 2024 | 62.22% |
| Jun 30, 2024 | 60.91% |
| Mar 31, 2024 | 59.93% |
| Dec 31, 2023 | 53.56% |
| Sep 30, 2023 | 47.39% |
| Jun 30, 2023 | 38.51% |
| Mar 31, 2023 | 35.32% |
| Dec 31, 2022 | -26.61% |
| Sep 30, 2022 | 16.28% |
| Jun 30, 2022 | -81.83% |
| Mar 31, 2022 | 10.43% |
| Dec 31, 2021 | -4.85% |
| Sep 30, 2021 | -19.24% |